story_ab49d44a-93b0-59fe-9100-6e98758460c9Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Verified signal
selinexor: 1 verified canonical event across 1 event type, supported by 1 independent source domain.
Why it matters
Verified with 1 independent source domain, 7 evidence object(s), 4 grounded fact(s), and confidence 0.80.
Evidence graph
evt_6f80ef86-497f-54bf-8eab-8adbb27f6910evd_0415889c-fc0c-544e-9be6-7501f8c06b44, evd_220df2bc-e37d-50d3-8577-7962f62b483b, evd_25ad3d72-27e1-5d33-9be0-f377c1333e62, evd_3112ba2e-1c2b-5023-9398-349c8b6fb275, evd_3a357ef6-41a1-59fa-849a-5a5ddcf3ce5a, evd_4b9ee43f-8ac1-5025-86b9-785849b02996, evd_d6b80efa-c464-54f8-8698-0621dcc9e411fact_11ced85e-4b2d-554c-94d0-fe89a8eaf2b7, fact_3b7b5326-2ff7-5f9c-adf1-35fd45c38a9c, fact_916dfcd8-a235-5128-9175-ebd9a65a1264, fact_ab19ce03-e226-5555-92b0-e503cbf9599erel_3098008c-048f-586e-a67b-d6843660a566, rel_4a725d23-778f-5ffe-9a55-c8bda9d9e6a1